Studies of secondary melanoma on C57BL/6J mouse liver using 1H NMR metabolomics

Metabolites

Volumn 3, Issue 4, 2013, Pages 1011-1035

  Feng, Ju ^a   Isern, Nancy G ^a   Burton, Sarah D ^a   Hu, Jian Zhi ^a  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

B16 F10 melanoma; Metabolomics; Multivariate analysis; NMR; PCA

Indexed keywords

CHOLESTEROL; CHOLINE; CREATINE; FUMARIC ACID; GLUCOSE; GLUTAMIC ACID; GLYCEROPHOSPHORYLCHOLINE; GLYCINE; HYPOXIA INDUCIBLE FACTOR; LONG CHAIN FATTY ACID; PHOSPHORYLCHOLINE; SUCCINIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADATION; CELL ACTIVITY; CELL HYPOXIA; CITRIC ACID CYCLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FATTY ACID OXIDATION; MALE; MELANOMA; METABOLITE; METABOLOMICS; METASTASIS; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL TRANSDUCTION;

MUS;

EID: 84897372851     PISSN: None     EISSN: 22181989     Source Type: Journal    
DOI: 10.3390/metabo3041011     Document Type: Article

References (65)

1. Beckonert, O.; Coen, M.; Keun, H.C.; Wang, Y.L.; Ebbels, T.M.D.; Holmes, E.; Lindon, J.C.; Nicholson, J.K. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat. Protoc. 2010, 5, 1019-1032.
2. Holmes, E.; Nicholson, J.K.; Nicholls, A.W.; Lindon, J.C.; Connor, S.C.; Polley, S.; Connelly, J. The identification of novel biomarkers of renal toxicity using automatic data reduction techniques and PCA of proton NMR spectra of urine. Chemom. Intell. Lab. Syst. 1998, 44, 245-255.
3. Watson, M. Drugs in clinical development for melanoma: Summary and table. Pharm. Med. 2012, 26, 171-183.
4. Jerant, A.F.; Johnson, J.T.; Sheridan, C.D.; Caffrey, T.J. Early detection and treatment of skin cancer. Am. Fam. Physician 2000, 62, 357-368.
5. Morvan, D.; Demidem, A.; Papon, J.; de Latour, M.; Madelmont, J.C. Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor sampled. Cancer Res. 2002, 62, 1890-1897.
6. Morvan, D.; Demidem, A.; Guenin, S.; Madelmont, J.C. Methionine-dependence phenotype of tumors: Metabolite profiling in a melanoma model using L-[methyl-13C]-methionine and high-resolution magic angle spinning 1H-13C nuclear magnetic resonance spectroscopy. Magn. Reson. Med. 2006, 55, 984-996.
7. Li, W.; Slominski, R.; Slominski, A.T. High-resolution magic angle spinning nuclear magnetic resonance analysis of metabolic changes in melanoma cells after induction of melanogenesis. Anal. Biochem. 2009, 386, 282-284.
8. Morvan, D.; Demidem, A.; Papon, J.; Madelmont, J.C. Quantitative HRMAS proton total correlation spectroscopy applied to cultured melanoma cells treated by chloroethyl nitrosourea: Demonstration of phospholipid metabolism alterations. Magn. Reson. Med. 2003, 49, 241-248.
9. Fages, A.; Morvan, D.; Schwartz, L.; Steyaert, J.M.; Stepien, G.; Demidem, A. Disturbance of metabolic pathways of glucose consumption by CENU treatment in B16 melanoma tumors: A NMR spectroscopy-based [1,2-13C]glucose fluxomics. Bull. du Cancer 2010, 97, S39-S40.
10. Guitera, P.; Bourgeat, P.; Stretch, J.R.; Scolyer, R.A.; Ourselin, S.; Lean, C.; Thompson, J.F.; Bourne, R. Diagnostic value of 8.5 T magnetic resonance spectroscopy of benign and malignant skin lesion biopsies. Melanoma Res. 2010, 20, 311-317.
11. Triba, M.N.; Starzec, A.; Bouchemal, N.; Guenin, E.; Perret, G.Y.; Le Moyec, L. Metabolomic profiling with NMR discriminates between biphosphonate and doxorubicin effects on B16 melanoma cells. NMR Biomed. 2010, 23, 1009-1016.
12. Bourne, R.M.; Stanwell, P.; Stretch, J.R.; Scolyer, R.A.; Thompson, J.F.; Mountford, C.E.; Lean, C.L. In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma. Eur. J. Radiol. 2005, 53, 506-513.
13. Stretch, J.R.; Somorjai, R.; Bourne, R.; Hsiao, E.; Scolyer, R.A.; Dolenko, B.; Thompson, J.F.; Mountford, C.E.; Lean, C.L. Melanoma metastases in regional lymph nodes are accurately detected by proton magnetic resonance spectroscopy of fine-needle aspirate biopsy samples. Ann. Surg. Oncol. 2005, 12, 943-949.
14. Maire, C.; Kluza, J.; Jendoubi, M.; Corazoa, P.; Guerreshi, P.; Touil, Y.; Polokowska, R.; Formstecher, P.; Mortier, L.; Marchetti, P. HIF-1 alpha is an important orchestrator of bioenergetic metabolism in melanoma. J. Investig. Dermatol. 2011, 131, 2152.
15. Comito, G.; Calvani, M.; Giannoni, E.; Bianchini, F.; Calorini, L.; Torre, E.; Migliore, C.; Giordano, S.; Chiarugi, P. HIF-1 alpha stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic. Biol. Med. 2011, 51, 893-904.
16. Trisciuoglio, D.; Gabellini, C.; Desideri, M.; Ziparo, E.; del Bufalo, D. Bcl-2 regulates HIF-1a protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90 beta. EJC Suppl. 2010, 8, 153-153.
17. Zaidi, M.R.; Day, C.P.; Merlino, G. From UVs to metastases: Modeling melanoma initiation and progression in the mouse. J. Investig. Dermatol. 2008, 128, 2381-2391.
18. Kim, S.H.; Kim, Y.; Kim, M.; Kim, D.S.; Lee, S.C.; Chi, S.W.; Lee, D.H.; Park, S.G.; Park, B.C.; Bae, K.H.; et al. Comparative proteomic analysis of mouse melanoma cell line B16, a metastatic descendant B16F10, and B16 overexpressing the metastasis-associated tyrosine phosphatase PRL-3. Oncol. Res. 2009, 17, 601-612.
19. Yoshimura, K.; Meckel, K.F.; Laird, L.S.; Chia, C.Y.; Park, J.J.; Olino, K.L.; Tsunedomi, R.; Harada, T.; Iizuka, N.; Hazama, S.; et al. Integrin alpha 2 mediates selective metastasis to the liver. Cancer Res. 2009, 69, 7320-7328.
20. Overwijk, W.W.; Restifo, N.P. B16 as a Mouse Model for Human Melanoma. In Current Protocols in Immunology; John Wiley & Sons, Inc.: Hoboken, NJ., USA, 2001.
21. Valle, E.F.; Zalka, A.D.; Groszek, L.; Stackpole, C.W. Patterning of B16-melanoma metastasis and colonization generally relates to tumor-cell growth-stimulating or growth-inhibiting effects of organs and tissues. Clin. Exp. Metastasis 1992, 10, 419-429.
22. Stackpole, C.W.; Valle, E.F.; Alterman, A.L. B16 melanoma metastasis to an artificial organ implant. Cancer Res. 1991, 51, 2444-2450.
23. Larue, L.; Beermann, F. Cutaneous melanoma in genetically modified animals. Pigment Cell Res. 2007, 20, 485-497.
24. Gheorgheosu, D.; Dehelean, C.; Cristea, M.; Muntean, D. Development of the B16 murine melanoma model. Ann. RSCB 2011, 2, 148-152.
25. Roomi, M.W.; Kalinovsky, T.; Roomi, N.W.; Ivanov, V.; Rath, M.; Niedzwiecki, A. Suppression of growth and hepatic metastasis of murine B16FO melanoma cells by a novel nutrient mixture. Oncol. Rep. 2008, 20, 809-817.
26. Beckonert, O.; Keun, H.C.; Ebbels, T.M.D.; Bundy, J.G.; Holmes, E.; Lindon, J.C.; Nicholson, J.K. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2007, 2, 2692-2703.
27. Washburn, K.W. A modification of the folch method of lipid extraction for poultry. Poult. Sci. 1989, 68, 1425-1427.
28. Iverson, S.J.; Lang, S.L.C.; Cooper, M.H. Comparison of the Bligh and Dyer and Folch methods for total lipid determination in a broad range of marine tissue. Lipids 2001, 36, 1283-1287.
29. Akoh, C.C.; Min, D.B. Food Lipids: Chemistry, Nutrition, and Biotechnology, 3rd ed.; Food Science and Technology: New York, NY., USA, 2008.
30. Govindaraju, V.; Young, K.; Maudsley, A.A. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000, 13, 129-153.
31. Martin, F.P.J.; Dumas, M.E.; Wang, Y.L.; Legido-Quigley, C.; Yap, I.K.S.; Tang, H.R.; Zirah, S.; Murphy, G.M.; Cloarec, O.; Lindon, J.C.; et al. A top-down systems biology view of microbiome-mammalian metabolic interactions in a mouse model. Mol. Syst. Biol. 2007, 3, 1-16.
32. Martin, F.P.J.; Wang, Y.L.; Sprenger, N.; Holmes, E.; Lindon, J.C.; Kochhar, S.; Nicholson, J.K. Effects of probiotic Lactobacillus Paracasei treatment on the host gut tissue metabolic profiles probed via magic-angle-spinning NMR spectroscopy. J. Proteome Res. 2007, 6, 1471-1481.
33. Forina, M.; Lanteri, S.; Oliveros, M.C.C.; Millan, C.P. Selection of useful predictors in multivariate calibration. Anal. Bioanal. Chem. 2004, 380, 397-418.
34. Huang, B.Y.; Kwock, L.; Castillo, M.; Smith, J.K. Association of choline levels and tumor perfusion in brain metastases assessed with proton MR spectroscopy and dynamic susceptibility contrast-enhanced perfusion weighted MRI. Technol. Cancer Res. Treat. 2010, 9, 327-337.
35. Aboagye, E.O. Phosphatidylcholine metabolic transformation and progression signature as a pharmacodynamic biomarker. Oncotarget 2010, 1, 163-166.
36. Schallreuter, K.U.; Hasse, S.; Rokos, H.; Chavan, B.; Shalbaf, M.; Spencer, J.D.; Wood, J.M. Cholesterol regulates melanogenesis in human epidermal melanocytes and melanoma cells. Exp. Dermatol. 2009, 18, 680-688.
37. Reynier, P.; Briane, D.; Cao, A.; Lievre, N.; Naejus, R.; Bissieres, P.; Salzmann, J.L.; Taillandier, E. In vitro and in vivo transfection of melanoma cells B16-F10 mediated by cholesterol-based cationic liposomes. J. Drug Target. 2002, 10, 557-566.
38. Jani, J.P.; Specht, S.; Stemmler, N.; Blanock, K.; Singh, S.V.; Gupta, V.; Katoh, A. Metastasis of B16f10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol-biosynthesis. Invasion Metastasis 1993, 13, 314-324.
39. McKnight, T.R.; Smith, K.J.; Chu, P.W.; Chiu, K.S.; Cloyd, C.P.; Chang, S.M.; Phillips, J.J.; Berger, M.S. Choline metabolism, proliferation, and angiogenesis in nonenhancing grades 2 and 3 astrocytoma. J. Magn. Reson. Imaging 2011, 33, 808-816.
40. Stewart, J.D.; Marchan, R.; Lesjak, M.S.; Lambert, J.; Hergenroeder, R.; Ellis, J.K.; Lau, C.H.; Keun, H.C.; Schmitz, G.; Schiller, J.; et al. Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis. Proc. Natl. Acad. Sci. USA 2012, 109, 8155-8160.
41. Moestue, S.A.; Borgan, E.; Huuse, E.M.; Lindholm, E.M.; Sitter, B.; Borresen-Dale, A.L.; Engebraaten, O.; Maelandsmo, G.M.; Gribbestad, I.S. Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer 2010, 10, 433.
42. Rocha, C.M.; Barros, A.S.; Gil, A.M.; Goodfellow, B.J.; Humpfer, E.; Spraul, M.; Carreira, I.M.; Melo, J.B.; Bernardo, J.; Gomes, A.; et al. Metabolic profiling of human lung cancer tissue by H-1 High Resolution Magic Angle Spinning (HRMAS) NMR spectroscopy. J. Proteome Res. 2010, 9, 319-332.
43. Patwardhan, G.A.; Liu, Y.Y. Sphingolipids and expression regulation of genes in cancer. Prog. Lipid Res. 2011, 50, 104-114.
44. Tajima, N.; Itokazu, Y.; Korpi, E.R.; Somerharju, P.; Kakela, R. Activity of BKCa channel is modulated by membrane cholesterol content and association with Na+/K+-ATPase in human melanoma IGR39 cells. J. Biol. Chem. 2011, 286, 5624-5638.
45. Benton, C.R.; Holloway, G.P.; Campbell, S.E.; Yoshida, Y.; Tandon, N.N.; Glatz, J.F.C.; Luiken, J.J.J.F.P.; Spriet, L.L.; Bonen, A. Rosiglitazone increases fatty acid oxidation and fatty acid translocase (FAT/CD36) but not carnitine palmitoyltransferase I in rat muscle mitochondria. J. Physiol. Lond. 2008, 586, 1755-1766.
46. Holloway, G.P.; Bezaire, V.; Heigenhauser, G.J.F.; Tandon, N.N.; Glatz, J.F.C.; Luiken, J.J.F.P.; Bonen, A.; Spriet, L.L. Mitochondrial long chain fatty acid oxidation, fatty acid translocase/CD36 content and carnitine palmitoyltransferase I activity in human skeletal muscle during aerobic exercise. J. Physiol. Lond. 2006, 571, 201-210.
47. Jakobs, B.S.; Wanders, R.J.A. Impaired peroxisomal fatty acid oxidation in human skin fibroblasts with a mitochondrial acylcarnitine carnitine translocase deficiency. J. Inherit. Metab. Dis. 1996, 19, 185-187.
48. Giordano, A.; Calvani, M.; Petillo, O.; Grippo, P.; Tuccillo, F.; Melone, M.A.B.; Bonelli, P.; Calarco, A.; Peluso, G. tBid induces alterations of mitochondrial fatty acid oxidation flux by malonyl-CoA-independent inhibition of carnitine palmitoyltransferase-1. Cell Death Differ. 2005, 12, 603-613.
49. Thupari, J.N.; Pinn, M.L.; Kuhajda, F.P. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem. Biophys. Res. Commun. 2001, 285, 217-223.
50. Kroemer, G.; Pouyssegur, J. Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell 2008, 13, 472-482.
51. Visarius, T.M.; Bahler, H.; Kupfer, A.; Cerny, T.; Lauterburg, B.H. Thiodiglycolic acid is excreted by humans receiving ifosfamide and inhibits mitochondrial function in rats. Drug Metab. Dispos. 1998, 26, 193-196.
52. Yokota, H.; Guo, J.F.; Matoba, M.; Higashi, K.; Tonami, H.; Nagao, Y. Lactate, choline, and creatine levels measured by vitro H-1-MRS as prognostic parameters in patients with non-small-cell lung cancer. J. Magn. Reson. Imaging 2007, 25, 992-999.
53. Howe, F.A.; Barton, S.J.; Cudlip, S.A.; Stubbs, M.; Saunders, D.E.; Murphy, M.; Wilkins, P.; Opstad, K.S.; Doyle, V.L.; McLean, M.A.; et al. Metabolic profiles of human brain tumors using quantitative in vivo H-1 magnetic resonance spectroscopy. Magn. Reson. Med. 2003, 49, 223-232.
54. Marchan, R.; Lesjak, M.S.; Stewart, J.D.; Winter, R.; Seeliger, J.; Hengstler, J.G. Choline-releasing glycerophosphodiesterase EDI3 links the tumor metabolome to signaling network activities. Cell Cycle 2012, 11, 4499-4506.
55. Moestue, S.A.; Giskeodegard, G.F.; Cao, M.D.; Bathen, T.F.; Gribbestad, I.S. Glycerophosphocholine (GPC) is a poorly understood biomarker in breast cancer. Proc. Natl. Acad. Sci. USA 2012, 109, E2506-E2506.
56. Miller, B.L. A review of chemical issues in 1H-NMR spectroscopy-N-acetyl-L-aspartate, creatine and choline. NMR Biomed. 1991, 4, 47-52.
57. Yu, J.; Kim, A.K. Effect of taurine on antioxidant enzyme system in B16F10 melanoma cells. Adv. Exp. Med. Biol. 2009, 643, 491-499.
58. Morvan, D.; Demidem, A. Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer Res. 2007, 67, 2150-2159.
59. Pollock, P.M.; Cohen-Solal, K.; Sood, R.; Namkoong, J.; Martino, J.J.; Koganti, A.; Zhu, H.; Robbins, C.; Makalowska, I.; Shin, S.S.; et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat. Genet. 2003, 34, 108-112.
60. Le, M.N.; Chan, J.L.K.; Rosenberg, S.A.; Nabatian, A.S.; Merrigan, K.T.; Cohen-Solal, K.A.; Goydos, J.S. The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells. J. Investig. Dermatol. 2010, 130, 2240-2249.
61. Rustin, P. Mitochondria, from cell death to proliferation. Nat. Genet. 2002, 30, 352-353.
62. Selak, M.A.; Armour, S.M.; MacKenzie, E.D.; Boulahbel, H.; Watson, D.G.; Mansfield, K.D.; Pan, Y.; Simon, M.C.; Thompson, C.B.; Gottlieb, E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7, 77-85.
63. Tiziani, S.; Lodi, A.; Khanim, F.L.; Viant, M.R.; Bunce, C.M.; Gunther, U.L. Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. PLoS One 2009, 4, e4251.
64. Burrows, N.; Babur, M.; Resch, J.; Williams, K.J.; Brabant, G. Hypoxia-inducible factor in thyroid carcinoma. J. Thyroid Res. 2011, 2011, Article ID 762905.
65. Jones, N.; Kim, P.J.; Agani, F. HIF-1 deficiency promotes hypoxia-induced cell death in melanoma cells. FASEB J. 2004, 18, A726-A727.